Description

5H-Thiazolo(3,2-A)Quinoline-4-Carboxylic Acid, 7-Fluoro-1-Methyl-5-Oxo -8-(1-Piperazinyl)-, Hydrate (2:1) is a high-purity, complex heterocyclic compound that serves as a critical advanced pharmaceutical intermediate. Its molecular architecture, featuring fused thiazoloquinoline and piperazine rings, makes it a valuable building block for the synthesis of novel active pharmaceutical ingredients (APIs). This compound is primarily targeted at research institutions and manufacturers in the pharmaceutical and biotechnology sectors engaged in the development of new therapeutic agents.

Application

• Pharmaceutical Intermediate: Key building block for the synthesis of novel antibiotic and antimicrobial agents targeting resistant bacterial strains.
• Medicinal Chemistry Research: Used in lead optimization and structure-activity relationship (SAR) studies for new drug candidates, particularly in anti-infective and anti-inflammatory research.
• Active Pharmaceutical Ingredient (API) Synthesis: Serves as a core scaffold or precursor in multi-step synthetic routes for complex target molecules.
• Biochemical Research: Potential use as a tool compound or probe in enzymatic and receptor-binding assays due to its specific heterocyclic structure.
• Contract Manufacturing (CMO): Supplied to custom synthesis organizations for the production of client-specific target molecules under cGMP conditions.

Basic Information

Product Name	5H-Thiazolo(3,2-A)Quinoline-4-Carboxylic Acid, 7-Fluoro-1-Methyl-5-Oxo -8-(1-Piperazinyl)-, Hydrate (2:1)
CAS No.	84339-08-2
Molecular Formula	C16H15FN4O3S · 0.5H2O
Molecular Weight	362.38 g/mol (Anhydrous basis)
Synonyms	7-Fluoro-1-methyl-5-oxo-8-(piperazin-1-yl)-5H-[1,3]thiazolo[3,2-a]quinoline-4-carboxylic acid hydrate (2:1); 8-(1-Piperazinyl)-7-fluoro-1-methyl-5-oxo-5H-thiazolo[3,2-a]quinoline-4-carboxylic acid hydrate; Thiazolo[3,2-a]quinoline-4-carboxylic acid, 7-fluoro-1-methyl-5-oxo-8-(1-piperazinyl)-, hydrate (2:1); Intermediate for Garenoxacin; Garenoxacin intermediate; BMS-284756 intermediate; T-3811 intermediate
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency suitable for pharmaceutical R&D and pre-clinical use. Quality is verified through a comprehensive suite of analytical techniques including HPLC, NMR, and MS. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting purity, identity, and impurity profiles. We support development with customized specifications to meet specific project requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed after opening to minimize exposure to atmospheric moisture. For long-term storage, consider desiccants or an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Water Content (KF)	2.0% - 4.0% (Theoretical for hydrate)
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Residual Solvents (GC)	Meets ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.